Notable candidates include MCC950, a selective NLRP3 inhibitor; anti–IL-1β monoclonal antibodies; and emerging GSDMD inhibitors, all of which aim to suppress the hyperinflammatory milieu of sepsis [136,137,138,139,140]. This evidence concerns the gene IL1B and Sepsis.